BLUE vs. ABBV

Last updated Apr 2, 2026

Compare and contrast key facts about bluebird bio, Inc. (BLUE) and AbbVie Inc. (ABBV).

Performance

BLUE vs. ABBV - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in bluebird bio, Inc. (BLUE) and AbbVie Inc. (ABBV). The values are adjusted to include any dividend payments, if applicable.

BLUE vs. ABBV - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
BLUE bluebird bio, Inc.	0.00%	-40.41%	-69.78%	-80.06%	-30.73%	-64.35%	-50.69%	-11.54%	-44.30%	188.65%
ABBV AbbVie Inc.	-5.16%	33.08%	18.86%	-0.23%	24.01%	32.43%	27.72%	1.47%	-0.96%	60.07%

Fundamentals

Total Revenue (TTM) BLUE : $103.95M ABBV : $61.16B
Gross Profit (TTM) BLUE : $28.19M ABBV : $44.85B
EBITDA (TTM) BLUE : -$115.82M ABBV : $28.29B

Returns By Period

BLUE

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

ABBV

• 1D: -1.15%
• 1M: -8.23%
• YTD: -5.16%
• 6M: -10.68%
• 1Y: 7.72%
• 3Y*: 14.56%
• 5Y*: 19.12%
• 10Y*: 18.93%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

BLUE vs. ABBV — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ABBV

ABBV Risk / Return Rank: 47
ABBV Sharpe Ratio Rank: 51
ABBV Sortino Ratio Rank: 43
ABBV Omega Ratio Rank: 43
ABBV Calmar Ratio Rank: 50
ABBV Martin Ratio Rank: 50

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BLUE vs. ABBV - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for bluebird bio, Inc. (BLUE) and AbbVie Inc. (ABBV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	BLUE	ABBV	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	0.29	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.85	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.74	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	0.74	—

Correlation

The correlation between BLUE and ABBV is 0.23, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

BLUE vs. ABBV - Dividend Comparison

BLUE has not paid dividends to shareholders, while ABBV's dividend yield for the trailing twelve months is around 3.09%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
BLUE bluebird bio, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ABBV AbbVie Inc.	3.09%	2.87%	3.49%	3.82%	3.49%	3.84%	4.41%	4.83%	3.89%	2.65%	3.64%	3.41%

Drawdowns

Drawdown Indicators

	BLUE	ABBV	Difference
Max Drawdown Largest peak-to-trough decline	—	-45.09%	—
Max Drawdown (1Y) Largest decline over 1 year	—	-16.31%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-21.92%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-45.09%	—
Current Drawdown Current decline from peak	—	-10.68%	—
Average Drawdown Average peak-to-trough decline	—	-10.70%	—
Ulcer Index Depth and duration of drawdowns from previous peaks	—	7.58%	—

Volatility

Volatility by Period

	BLUE	ABBV	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	7.61%	—
Volatility (6M) Calculated over the trailing 6-month period	—	18.69%	—
Volatility (1Y) Calculated over the trailing 1-year period	—	27.07%	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	—	22.62%	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	—	25.70%	—

Financials